Search research articles
Contact Us
Filters
Showing results (41-50 of 58) with videos related to
Page
of 6
Sort By:
Diabetes Care
|
March 2, 2022
Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose
Mariam Alatrach, Christina Agyin, Carolina Solis-Herrera, et al.
Diabetes
|
April 1, 2018
Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy
Robert Martinez, Hussein Al-Jobori, Ali M Ali, et al.
BMJ Open Diabetes Research & Care
|
October 18, 2024
Effect of weight-maintaining ketogenic diet on glycemic control and insulin sensitivity in obese T2D subjects
Aurora Merovci, Brittany Finley, Andrea Hansis-Diarte, et al.
The Journal of Clinical Endocrinology and Metabolism
|
January 18, 2018
Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus
Hussein Al Jobori, Giuseppe Daniele, John Adams, et al.
The Journal of Clinical Endocrinology and Metabolism
|
August 4, 2020
Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM
Ali Muhammed Ali, Andrea Mari, Robert Martinez, et al.
Diabetes Care
|
July 8, 2025
Changes in β-Cell Function and Insulin Sensitivity During Treatment With Dapagliflozin Alone or in Combination With Exenatide in Type 2 Diabetes
Curtis Triplitt, Eugenio Cersosimo, Mariam Alatrach, et al.
Hepatology (Baltimore, Md.)
|
September 18, 2016
Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study
Amalia Gastaldelli, Melania Gaggini, Giuseppe Daniele, et al.
Diabetes, Obesity & Metabolism
|
May 18, 2022
Type 2 diabetes subgroups and response to glucose-lowering therapy: Results from the EDICT and Qatar studies
Tamam Abdul-Ghani, Curtiss Puckett, Osama Migahid, et al.
The Journal of Clinical Endocrinology and Metabolism
|
July 22, 2023
Emergence of a New Glucoregulatory Mechanism for Glycemic Control With Dapagliflozin/Exenatide Therapy in Type 2 Diabetes
Eugenio Cersosimo, Mariam Alatrach, Carolina Solis-Herrera, et al.
International Journal of Molecular Sciences
|
August 26, 2022
Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects
Anthony H Cincotta, Eugenio Cersosimo, Mariam Alatrach, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 58) with videos related to
Sort By:
Page
of 6
Diabetes Care
|
March 2, 2022
Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose
Mariam Alatrach, Christina Agyin, Carolina Solis-Herrera, et al.
Diabetes
|
April 1, 2018
Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy
Robert Martinez, Hussein Al-Jobori, Ali M Ali, et al.
BMJ Open Diabetes Research & Care
|
October 18, 2024
Effect of weight-maintaining ketogenic diet on glycemic control and insulin sensitivity in obese T2D subjects
Aurora Merovci, Brittany Finley, Andrea Hansis-Diarte, et al.
The Journal of Clinical Endocrinology and Metabolism
|
January 18, 2018
Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus
Hussein Al Jobori, Giuseppe Daniele, John Adams, et al.
The Journal of Clinical Endocrinology and Metabolism
|
August 4, 2020
Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM
Ali Muhammed Ali, Andrea Mari, Robert Martinez, et al.
Diabetes Care
|
July 8, 2025
Changes in β-Cell Function and Insulin Sensitivity During Treatment With Dapagliflozin Alone or in Combination With Exenatide in Type 2 Diabetes
Curtis Triplitt, Eugenio Cersosimo, Mariam Alatrach, et al.
Hepatology (Baltimore, Md.)
|
September 18, 2016
Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study
Amalia Gastaldelli, Melania Gaggini, Giuseppe Daniele, et al.
Diabetes, Obesity & Metabolism
|
May 18, 2022
Type 2 diabetes subgroups and response to glucose-lowering therapy: Results from the EDICT and Qatar studies
Tamam Abdul-Ghani, Curtiss Puckett, Osama Migahid, et al.
The Journal of Clinical Endocrinology and Metabolism
|
July 22, 2023
Emergence of a New Glucoregulatory Mechanism for Glycemic Control With Dapagliflozin/Exenatide Therapy in Type 2 Diabetes
Eugenio Cersosimo, Mariam Alatrach, Carolina Solis-Herrera, et al.
International Journal of Molecular Sciences
|
August 26, 2022
Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects
Anthony H Cincotta, Eugenio Cersosimo, Mariam Alatrach, et al.
Page
of 6